Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 100   

Articles published

CBST 73.59 +0.22 (0.30%)
price chart
Cubist Pharmaceuticals Inc's Momentum Builds As Anti-Infection Product Line ...
Last year, Cubist acquired Dificid when it bought Optimer Pharmaceuticals for $551 million, and Dificid's sales total $47.7 million through the first nine months of 2014.
Cubist Pharmaceuticals Q3 Earnings Beat Expectations  Zacks.com
Trade-Ideas: Cubist Pharmaceuticals (CBST) Is Today's "Storm The ...  TheStreet.com
Related articles »  
New Cubist Pharmaceuticals chief executive will be Robert J. Perez
Cubist Pharmaceuticals Inc. said Monday it plans to install a new chief executive, a surprise move that raised questions about whether the Lexington company will keep expanding as the leading US maker of antibiotics or become a takeover target.
Cubist Pharmaceuticals Names Robert J. Perez Chief Executive Officer  Yahoo Finance UK
Related articles »  
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
Cubist Pharmaceuticals (NASDAQ: CBST ) and Durata Therapeutics (NASDAQ: DRTX ) both won this week with nods by the FDA's advisory panels on each company's antibacterial agents. In two unanimous votes, the FDA panels agreed on the safety and ...
Related articles »  
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
Given the bipolar nature of regulatory decisions for biotechs, it's key to understand the risks relative to rewards associated with a company ahead of the event. With that in mind, here is a Foolish comparison of two biotechs, Cubist Pharmaceuticals ...
Cubist Pharmaceuticals (CBST) Upgraded From Hold to Buy
CUBIST PHARMACEUTICALS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago.
Wedbush Begins Coverage on Cubist Pharmaceuticals (CBST)  Ticker Report
Cubist Pharmaceuticals Raised to Buy at TheStreet (CBST)  WKRB News
Related articles »  
Cubist Pharmaceuticals: Ripe For Acquisition?
Threats from the increase in drug-resistant germs, and the subsequent rise in demand for more effective and high-impact antibiotics has spurred interest in companies such as Cubist Pharmaceuticals Inc (CBST). The Massachusetts-based drug developer has ...
Cubist Battling Superbugs Offers Remedy for J&J: Real M&A  Businessweek
Lilly among those eyeing antibiotic maker Cubist, analyst says  Indianapolis Business Journal
Related articles »  
Wedbush Initiates Coverage On Cubist Pharmaceuticals
Wedbush initiated coverage on Cubist Pharmaceuticals Inc (NASDAQ: CBST) with a Neutral rating and $70 price target. Analysts led by Heather Behanna commented that "Cubist is in transition from a one-product company to a leader in the antibiotic arena.
Cubist Pharmaceuticals Given "BBB-" Credit Rating (CBST)  WKRB News
Cubist Pharmaceuticals Receives New Coverage from Analysts at SunTrust ...  Ticker Report
Related articles »  
Cubist Pharmaceuticals Rating Lowered to Neutral at Credit Suisse (CBST)
Cubist Pharmaceuticals Inc logo Cubist Pharmaceuticals (NASDAQ:CBST) was downgraded by equities researchers at Credit Suisse from an �outperform� rating to a �neutral� rating in a research report issued on Thursday, TheFlyOnTheWall.
Cubist Pharmaceuticals Larger Than S&P 500 Component PerkinElmer
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Cubist Pharmaceuticals Inc. (Symbol: CBST) was identified as having a larger market cap than the smaller end of the S&P 500, for example PerkinElmer, Inc.
Related articles »  
Cubist Pharmaceuticals Inc. (CBST): Poised To Pop on FDA OK
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) is slated to hear from the government agency before the end of June. Cubist is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care ...
FDA approves new Cubist antibiotic  Boston Globe
Cubist completes exacta, gets good news from FDA two days in a row  MarketWatch (blog)
Related articles »